Mylan NV
Find Ratings Reports
0.74 |
1.93%
MYLAN NV's gross profit margin for the first quarter of its fiscal year 2017 is essentially unchanged when compared to the same period a year ago. The company managed to grow both sales and net income at a faster pace than the average competitor in its industry this quarter as compared to the same quarter a year ago. MYLAN NV has weak liquidity. Currently, the Quick Ratio is 0.85 which shows a lack of ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.
During the same period, stockholders' equity ("net worth") has increased by 13.45% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
| Income Statement | Q1 FY17 | Q1 FY16 |
|---|---|---|
| Net Sales ($mil) | 2719.5 | 2191.3 |
| EBITDA ($mil) | 783.2 | 543.6 |
| EBIT ($mil) | 367.7 | 246.5 |
| Net Income ($mil) | 66.4 | 13.9 |
| Balance Sheet | Q1 FY17 | Q1 FY16 |
|---|---|---|
| Cash & Equiv. ($mil) | 981.6 | 1306.5 |
| Total Assets ($mil) | 34272.6 | 22644.1 |
| Total Debt ($mil) | 14959.0 | 7474.6 |
| Equity ($mil) | 11656.0 | 10273.4 |
| Profitability | Q1 FY17 | Q1 FY16 |
|---|---|---|
| Gross Profit Margin | 56.13 | 56.49 |
| EBITDA Margin | 28.79 | 24.8 |
| Operating Margin | 13.52 | 11.25 |
| Sales Turnover | 0.34 | 0.43 |
| Return on Assets | 1.55 | 3.55 |
| Return on Equity | 4.56 | 7.83 |
| Debt | Q1 FY17 | Q1 FY16 |
|---|---|---|
| Current Ratio | 1.56 | 1.67 |
| Debt/Capital | 0.56 | 0.42 |
| Interest Expense | 128.2 | 54.1 |
| Interest Coverage | 2.87 | 4.56 |
| Share Data | Q1 FY17 | Q1 FY16 |
|---|---|---|
| Shares outstanding (mil) | 535.93 | 491.36 |
| Div / share | 0.0 | 0.0 |
| EPS | 0.12 | 0.03 |
| Book value / share | 21.75 | 20.91 |
| Institutional Own % | n/a | n/a |
| Avg Daily Volume | 5759732.0 | 5296107.0 |
HOLD. The current P/E ratio indicates a significant discount compared to an average of 84.59 for the Pharmaceuticals industry and a significant premium compared to the S&P 500 average of 25.73. To use another comparison, its price-to-book ratio of 1.70 indicates a discount versus the S&P 500 average of 3.08 and a significant discount versus the industry average of 10.76. The price-to-sales ratio is below the S&P 500 average and is well below the industry average, indicating a discount. Upon assessment of these and other key valuation criteria, MYLAN NV proves to trade at a discount to investment alternatives within the industry.
| Price/Earnings |
|
Price/Cash Flow |
| |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MYL 36.98 | Peers 84.59 | MYL 8.21 | Peers 19.60 | |||||||||||||||||||||
|
Discount. A lower P/E ratio than its peers can signify a less expensive stock or lower growth expectations. MYL is trading at a significant discount to its peers. |
Discount. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures. MYL is trading at a significant discount to its peers. |
|||||||||||||||||||||||
| Price/Projected Earnings |
|
Price to Earnings/Growth |
|
|||||||||||||||||||||
| MYL 6.48 | Peers 16.00 | MYL 0.08 | Peers 0.70 | |||||||||||||||||||||
|
Discount. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth expectations. MYL is trading at a significant discount to its peers. |
Discount. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples. MYL trades at a significant discount to its peers. |
|||||||||||||||||||||||
| Price/Book |
|
Earnings Growth |
|
|||||||||||||||||||||
| MYL 1.70 | Peers 10.76 | MYL -35.90 | Peers 19.71 | |||||||||||||||||||||
|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet. MYL is trading at a significant discount to its peers. |
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios. However, MYL is expected to significantly trail its peers on the basis of its earnings growth rate. |
|||||||||||||||||||||||
| Price/Sales |
|
Sales Growth |
|
|||||||||||||||||||||
| MYL 1.71 | Peers 11.00 | MYL 19.04 | Peers 5.56 | |||||||||||||||||||||
|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales. MYL is trading at a significant discount to its industry on this measurement. |
Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share. MYL has a sales growth rate that significantly exceeds its peers. |
|||||||||||||||||||||||
